Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Concerns over lindane treatment for scabies and lice

Eric Wooltorton
CMAJ May 27, 2003 168 (11) 1447-1448;
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: Scabies and lice infestations are common afflictions often remedied with topical therapies such as lindane,1,2 a drug prescribed more than a million times last year in the United States.3 However, lindane has several serious neurotoxic effects, ranging from dizziness, headaches and paresthesia, to seizures and even death.4 The US Food and Drug Administration recently advised that these effects are more common in young children, elderly people and people weighing less than 50 kg and has recommended that the drug be used only as a second-line agent.4

The conditions: Scabies is caused by the mite Sarcoptes scabiei. The mites die if away from a human host for more than 72 hours.5 Impregnated females (about 0.3 mm long) are transferred directly through close contact with people, bedding or clothing. They lay their eggs as they burrow under the skin, and after 3–4 days the larvae hatch and migrate to the skin surface, creating new burrows, where they mature into reproducing adults. Infestations often involve as few as 5–10 adult mites.5 Elderly and immunocompromised hosts are at risk for a severe “crusted” form of scabies.1,5 Initial infestations may be relatively asymptomatic for the first 4–6 weeks. In subsequent infestations, an intense, generalized, often nocturnal itch can develop within days. Pruritic lesions erupt along mite burrows in the finger webs, penis, breasts, and folds of the wrists, elbows and knees.1,5 Secondary bacterial infections can occur, as can a papular rash on the buttocks, scapula and abdomen. Scabies is diagnosed clinically, aided by skin scrapings showing mites, ova or feces.5 Treatment of asymptomatic close contacts is advisable to avoid reinfestation.

Head lice infestation (pediculosis capitis) is caused by Pediculus humanus capitis.2,6 These lice live close to the scalp for easy access to blood and warmth and will die without a human host within 1–2 days. Adult lice are transferred through close human contact or through contact with hats and other headgear, pillow cases and clothing. Daily, female lice lay up to 6 yellow-white, 1-mm long oval eggs, or nits.6,7 Nits are cemented to the base of the hair shaft, typically within 6.5 mm of the scalp.6 After a week, a pinhead-sized nymph hatches and, within a week, matures into an adult the size of a sesame seed.7 Most infestations are asymptomatic, but local reactions to the louse saliva can cause a tickly or itchy scalp sensation. Secondary bacterial infections can occur. Close contacts should be checked and treated if infested.8

For scabies and head lice infestations, contaminated clothing and toys need to be laundered in hot water, or isolated in a plastic bag for 2 weeks or more.2 Pets do not carry scabies mites or human lice.

The drugs: Lindane (gamma benzene hexachloride), a lipophilic insecticide, has been used since the 1950s.4 Although most serious neurotoxic effects result from misuse of the product, one-fifth occur in patients using the drug appropriately.4 At particular risk are elderly people, young children and people weighing less than 50 kg,4 possibly because of increased systemic absorption and neurologic susceptibilities. Lindane is contraindicated in people with seizure disorders4 and should be used cautiously in those at risk of seizures (e.g., people taking HIV treatments, antipsychotics, bupropion, systemic steroids, quinolone antibiotics or antimalarial drugs, and people with head injuries or intracranial lesions, eating disorders, or benzodiazepine or ethanol abuse).4 Toxic effects can be minimized by applying small amounts of the drug for shorter than normal periods, by avoiding open sores, the eyes and the mouth, and by not repeating treatment or by maximizing the time between treatments.9,10 Lindane is absorbed more rapidly into warm, wet or oily skin, or skin that is covered with occlusive diapers, shower caps or tight clothes.10 Pregnant women should preferentially use alternative treatments (see below) but may use lindane cautiously if other therapies have failed or are inappropriate.11 Breast-feeding women should pump and discard milk for at least 24 hours after using lindane.9

Several scabicides and pediculocides are commonly prescribed in Canada (Table 1). Local resistance, particularly of lice, to agents such as synthetic pyrethroids and permethrin may result in treatment failures.12 DDT, malathion, carbamate agents and oral ivermectin are not available in Canada. Combining a topical treatment with an oral antibiotic (e.g., trimethoprim–sulfamethoxazole) may increase the success of head lice treatment.13

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

An alternative scabies treatment for pregnant or lactating women and children less than 2 months old is precipitated sulfur 6% in petrolatum.14

“Wet combing” — a nontoxic (but less efficacious) alternative to pediculocides — involves coating the scalp liberally with conditioner and removing lice and nits with a fine-tooth comb every few days.6 There are limited efficacy data for the topical acetomicellar complex of acetic acid, citronella oil and camphor (SH-206)8 or for formic acid preparations,14 topical vinegar and mineral oil mixtures, or several herbal products.14 A note of caution, however: “pound for pound” some “natural” therapies such as tea-tree oil may be more toxic to mammals than chemical treatments.15

What to do: Patients susceptible to scabies and head lice infestations include children and elderly people,5,6 homeless people16 and people in institutions,1 and they may be the most vulnerable to the adverse effects of agents such as lindane.4 Alternative agents may be preferable for first-line treatment in these and other cases. In the United States, patient exposure is being minimized by strict warnings on lindane product labels and limits on lindane package sizes.4 It is unknown yet whether Canada will follow this lead.

Eric Wooltorton CMAJ

References

  1. 1.↵
    Chosidow O. Scabies and pediculosis. Lancet 2000;355:819-26.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Weir E. School's back, and so is the lowly louse. CMAJ 2001;165(6):814.
    OpenUrlFREE Full Text
  3. 3.↵
    Lindane shampoo and lindane lotion questions and answers. Rockville (MD): Center for Drug Evaluation and Research, US Food and Drug Administration; 2003. Available: www.fda.gov/cder/drug/infopage/lindane/lindaneQA.htm (updated 2003 Apr 15; accessed 2003 May 6).
  4. 4.↵
    FDA public health advisory: safety of topical lindane products for the treatment of scabies and lice. Rockville (MD): Center for Drug Evaluation and Research, US Food and Drug Administration; 2003. Available: www.fda.gov/cder/drug/infopage/lindane/lindanePHA.htm (updated 2003 Mar 28; accessed 2003 May 6).
  5. 5.↵
    Wendel K, Rompalo A. Scabies and pediculosis pubis: an update of treatment regimens and general review. Clin Infect Dis 2002;35(Suppl 2):S146-51.
  6. 6.↵
    Roberts RJ. Head lice. N Engl J Med 2002;346: 1645-50.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Head lice. Atlanta: Division of Parasitic Diseases, US Centers for Disease Control and Prevention. Available: www.dpd.cdc.gov/dpdx/HTML/Frames/G-L/HeadLice/body_Headlice_page1.htm (modified 2002 Dec 9; accessed 2003 May 6).
  8. 8.↵
    Hoey J. The facts of lice. CMAJ 1997;157(6):747.
    OpenUrlFREE Full Text
  9. 9.↵
    Medication guide: lindane (LIHN-dane) shampoo USP, 1%. Rockville (MD): Center for Drug Evaluation and Research, US Food and Drug Administration; 2003. Available: www.fda.gov/cder/drug/infopage/lindane/lindaneShampooGuide.htm (updated 2003 Mar 28; accessed 2003 May 6).
  10. 10.↵
    Medication guide: lindane (LIHN-dane) lotion USP, 1%. Rockville (MD): Center for Drug Evaluation and Research, US Food and Drug Administration; 2003. Available: www.fda.gov/cder/drug/infopage/lindane/lindaneLotionGuide.htm (updated 2003 Mar 28; accessed 2003 May 6).
  11. 11.↵
    Koren G, editor. Maternal–fetal toxicology. A clinician's guide. 3rd ed. New York: Marcel Dekker; 2001. p. 115-8.
  12. 12.↵
    Dodd C. Treatment of lice. BMJ 2001;323:1084.
    OpenUrlFREE Full Text
  13. 13.↵
    Hipolito RB, Mallorca FG, Zuniga-Macaraig ZO, Apolinario PC, Wheeler-Sherman J. Head lice infestation: single drug versus combination therapy with one percent permethrin and trimethoprim/sulfamethoxazole. Pediatrics 2001;107(3):E30.
  14. 14.↵
    Patient self-care. Helping patients make therapeutic choices. Ottawa: Canadian Pharmacists Association; 2002. p. 592-621.
  15. 15.↵
    Crossan L. Experience-based treatment of head lice. BMJ 2002;324:1220.
    OpenUrlFREE Full Text
  16. 16.↵
    Hwang SW. Homelessness and health. CMAJ 2001;164(2):229-33.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 168, Issue 11
27 May 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Concerns over lindane treatment for scabies and lice
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Concerns over lindane treatment for scabies and lice
Eric Wooltorton
CMAJ May 2003, 168 (11) 1447-1448;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Concerns over lindane treatment for scabies and lice
Eric Wooltorton
CMAJ May 2003, 168 (11) 1447-1448;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Alternatives to lindane
  • Alternatives to lindane
  • Google Scholar

More in this TOC Section

Practice

  • Phthiriasis palpebrarum
  • Penicillin allergy delabelling in pregnancy
  • Penicillin allergy delabelling of patients at risk of sexually transmitted infections in primary care
Show more Practice

Health and Drug Alerts

  • Nefazodone (Serzone) withdrawn because of hepatotoxicity
  • Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex)
  • Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Show more Health and Drug Alerts

Similar Articles

Collections

  • Topics
    • Dermatology
    • Pharmacology & toxicology
    • Public health

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire